Navigation Links
IPF in Medical News

Large clinical trial finds pirfenidone may help lung function in IPF patients

ATS 2009, SAN DIEGOA large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF. In a Phase III clinical study program called "CAPACITY," investigators di...

Mike Bridges Takes Home Four Gold Medals at IPF Masters World Powerlifting Championships; Says NutraCea's RiSolubles(R) is an Essential Part of his Training Regimen

PHOENIX, Oct. 21 /PRNewswire/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran (SRB) nutrient research and technology, announced today that world champion powerlifter Mike Bridges received four gold medals for his performances in the squat, bench press and dead li...

Smoking Worsens Prognosis for IPF Patients

Study tackles anomaly that current puffers live longer with untreatable lung disease MONDAY, Jan. 21 (HealthDay News) -- Current and former smokers with the lung disease idiopathic pulmonary fibrosis (IPF) have a worse prognosis than nonsmokers, says a British study. IPF is untre...

Smoking belies milder disease but worse prognosis for IPF patients

Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London. Previous research had counter-intuitively suggested t...

CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget

Success of 2007 National IPF Awareness Week on Capitol Hill Drives Efforts to Increase Research, Awareness for Deadly Lung Disease SAN JOSE, Calif., Oct. 4 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced that the success of its fifth annual National IPF ...

CPF Announces National IPF Awareness Week Activities

SAN JOSE, Calif., Sept. 21 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis today announced 2007 National IPF Awareness Week activities that include a patient event this weekend in Washington, D.C., a congressional reception that includes a tribute to late Rep. Charlie Norwood, ...

In brief: New prognostic indicator for patients with IPF

There may be a new way to predict mortality in patients with idiopathic pulmonary fibrosis (IPF), a devastating disease that slowly petrifies the lungs. Most patients live only three years after diagnosis on average; however, some remain stable for many years, while for others, the disease progres...

Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF

Events held in Chicago and Los Angeles provide foundation for new education and research efforts to fight IPF SAN JOSE, Calif., Oct. 29 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is pleased to announce that two major fundraising events hosted in Chicago and Los ...

Genetic Breakthrough Spells Hope for Lung Fibrosis Patients

...ed the gene activity profile of the lungs of eight ipf patients who were experiencing dramatic worsening of their disease when they died, 23 stable ipf patients and 15 people with healthy lungs. Diff... expression of nearly 600 genes were noted between ipf patients with accelerated disease and those with s...

Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference

...tive Officer, added, "Our LPA1 program is particularly important for Amira. ipf is a specialty focused disease setting and presents the opportunity for Ami...alization without the assistance of a strategic partner. Most importantly, ipf is a grievous disease with minimally effective therapeutic options for pati...
IPF in Medical Technology

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients - - Results of new analyses of efficacy and safety reported - - Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) - SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN...

InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3

BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a confer...

InterMune Announces Progress on Pirfenidone in IPF

- Initiating planned roll-over study for CAPACITY patients in Q3 - - Patient retention and conduct of Phase 3 CAPACITY program remain excellent to date - - Abstract of Shionogi Phase 3 pirfenidone study now available on ATS website -...

Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients

CPF-Funded Research Manuscript Appears in Peer-Review Journal Respiratory Medicine SAN JOSE, Calif., March 21, 2007 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced a summary manuscript from its Basic Research Questionnaire, considered one of the largest databases of info...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...folio includes the Phase III program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with ipf and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound R7227 (ITMN-191)...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191

...(HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with ipf and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-19...

InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009

...rtfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with ipf and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-1...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

...rtfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with ipf and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes HCV protease inhibitor ITMN-191 (R7227) in ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...PF), a condition in which the lungs become scarred over time, making it more and more difficult to breathe(6). Early clinical trial results in ipf did not show a significant treatment benefit over placebo, and clinical trials have therefore been halted. About Gleevec Gleevec(R) (imatinib m...
IPF in Medical Products

i.Series™ Plasma Storage Freezer (-30C)

Description:... Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost times....
Company:Helmer, Inc.
IPF in Biological News

Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients

...and Critical Care Medicine addresses a dilemma in ipf care that currently is unsolved. "Approximately...al is about three years. For unknown reasons, some ipf patients experience rapid declines that cause diff...ed the gene activity profile of the lungs of eight ipf patients whose disease was dramatically worsening ...

UT Southwestern researchers identify gene linked to inherited form of fatal lung disease

...antation is an option, but most people who develop ipf are older than that." The ultimate goal, Dr. Ga...on of this pulmonary condition. About one in 50 ipf patients have an inherited form of the disease. It...s in which multiple individuals were affected with ipf to search for a gene causing the disease. This led...

Extra-aggressive form of idiopathic pulmonary fibrosis identified

...h May, strong evidence indicating that a subset of ipf patients has a short duration of symptoms before d...ed to collect as much information on patients with ipf as possible. "We are only now starting to really u...o be seen in centers that are actively involved in ipf research." Better identification and understa...

Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

...t. Based on observations in the clinic that some ipf patients display a more rapidly progressing diseas... "We are only now starting to really understand ipf and to characterize it," Dr. Kaminski said. "There...o be seen in centers that are actively involved in ipf research, so we can help them better decide a cour...

Discovery of an HIV inhibitor in human blood points to new drug class

...ence that HIV-1 does not easily develop resistance to VIRIP, at least in cell culture. Furthermore, their collaborators led by Wolf-Georg Forssmann of ipf PharmaCeuticals GmbH and Hannover Medical School found preliminary evidence showing that some derivatives of the peptide are highly stable in human bl...
IPF in Biological Technology

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT - - Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT - - Conference call and webcast Tuesday, May 19, 6 p.m. PDT - BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMun...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

- CAPACITY 2 Meets Primary and Key Secondary Endpoints - - CAPACITY 1 Misses Primary Endpoint, Provides Supportive Data - - Company Preparing to Submit NDA and MAA - BRISBANE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced results from the...

InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF

- Provides Progress Report on InterMune Phase 3 CAPACITY Program - - Reports 97% patient retention rate in CAPACITY - BRISBANE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today reported that on October 16, 2008, the Japanese Ministry of Health, Labo...

InterMune to Present at Canaccord Adams Conference

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibit...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...om the Phase 3 CAPACITY program for pirfenidone in ipf were presented in an oral late-breaker session on ...onsistent with the Phase 3 study of pirfenidone in ipf patients conducted by Shionogi & Co. Ltd. in J...idone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is ...

InterMune to Release Second Quarter Financial Results on August 6

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...for pirfenidone role in treatment of patients with ipf - - Ground-breaking data from INFORM-1 study;...idone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is ... the prior clinical experience with pirfenidone in ipf patients. Pirfenidone failed to achieve statistic...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune to Release First Quarter Financial Results on April 30

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...
Other Tags
(Date:8/28/2014)... 2014) Solid-head power toothbrushes retain less bacteria ... The University of Texas Health Science Center at ... the study are published in the August issue ... and professor at the UTHealth School of Dentistry, ... counts were lower in the solid-head toothbrush group ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... prevent Ebola virus disease will begin next week by ... part of the National Institutes of Health. , The ... vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will ... an immune system response in healthy adults. Testing will ... Maryland. , The study is the first of several ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
(Date:8/28/2014)... 2014 Dyslexia, the most commonly diagnosed learning ... reading disability that occurs when the regions of ... normally. , The use of non-invasive functional neuroimaging ... disrupted in dyslexia. However, most prior work has ... regions, leaving a gap in our understanding of ...
(Date:8/28/2014)... Washington, Oregon, northern California, and Alaska totaled 515 million ... 2014, an increase of more than 10 percent compared ... Service,s Pacific Northwest Research Station reported today. During this ... percent to 247 million board feet. , The total ... 5 percent to $390 million in the same quarter, ...
(Date:8/27/2014)... FREMONT, Calif. , Aug. 27, 2014  WaferGen ... completed its previously announced underwritten public offering of units ... $10,000 per unit for gross proceeds of $20 million, ... expenses payable by the Company.  The shares and warrants ... Each unit sold in the offering consists ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2West coast log exports up, lumber exports down in second quarter of 2014 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
Other Contents